Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

And it might even get worse for Regeneron since Amgen's Pavblu, a biosimilar version of Eylea, hit the market only six months ago. In the fourth quarter, combined U.S. sales of Eylea and Eylea HD ...

And also the Eylea, I mean, the high concentration we ... which is pretty unique and strong. We know that Amgen launched at risk. So we have not committed to launch that product into U.

The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...

Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...

Eylea, which Regeneron Pharmaceuticals ... ranks tenth on our list of the 11 best pharma stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers ...